Rajasekaran Mahalingam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rajasekaran Mahalingam has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Frank McKeon
Stem Cell Center, Department of Biology and Biochemistry, University of Houston, Houston, TX 77003, USA
4 shared publications - Wa Xian
Stem Cell Center, Department of Biology and Biochemistry, University of Houston, Houston, TX 77003, USA
4 shared publications Yanting Zhang
University of Houston, Houston, TX
4 shared publicationsAudrey-Ann Liew
University of Houston, Houston, TX
3 shared publicationsMarcin Duleba
University of Houston, Houston, TX
3 shared publicationsChristopher Crum
Harvard Medical School, Boston, MA
2 shared publications
Latest Publications
- 21 July 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (11) , 2609-2620
Carboplatin induces optic nerve oligodendrocyte loss and impairs myelin sheath microstructure in a mouse model of neurofibromatosis type 1
Background: Vision impairment is a significant concern for children with neurofibromatosis type 1 (NF1)-associated optic pathway glioma (OPG). While carboplatin-containing chemotherapy is often first-line therapy for NF1-OPG, it does not consistently improve visual function. Furthermore, chemotherapy is associated with altered white matter microstructure in individuals with NF1-OPG, suggesting a detrimental effect on oligodendroglia. We analyzed the tumor-independent effects of carboplatin on oligodendrocytes in Nf1-mutant mice and evaluated pharmacological strategies for reducing this chemotherapy-associated toxicity. Methods: Carboplatin- or vehicle-treated Nf1+/− mice or Nf1-mutant optic glioma cells were employed to assess the effects of restorative interventions on optic nerve oligodendrocytes in vivo and tumor cell growth in vitro, respectively. Results: Clinically relevant carboplatin dosing induced oligodendrocyte loss and impaired myelin sheath structure in the optic nerves of Nf1+/− mice, an effect not observed following vinca alkaloids or MEK inhibitor (selumetinib) treatment. Carboplatin downregulates genes essential for cholesterol biosynthesis and decreases cholesterol levels in Nf1+/− optic nerves, such that dietary cholesterol supplementation after carboplatin exposure restored oligodendrocyte numbers. Carboplatin also increases the density of monocytes (microglia/macrophages) in the Nf1+/− optic nerves. Using PLX5622 (a CSF1R inhibitor) to reduce monocyte numbers or using clemastine to promote the generation and survival of oligodendrocytes, alleviated the oligodendrocyte loss caused by carboplatin treatment. Notably, PLX5622 and clemastine reduced the viability of Nf1-mutant optic glioma tumor cells. Conclusions: Our findings demonstrate that carboplatin induces oligodendroglial toxicity in Nf1-mutant optic nerves, which can be mitigated by clemastine, PLX5622, or dietary cholesterol following carboplatin exposure.
- 21 July 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (11) , 2609-2620
Carboplatin induces optic nerve oligodendrocyte loss and impairs myelin sheath microstructure in a mouse model of neurofibromatosis type 1
Background: Vision impairment is a significant concern for children with neurofibromatosis type 1 (NF1)-associated optic pathway glioma (OPG). While carboplatin-containing chemotherapy is often first-line therapy for NF1-OPG, it does not consistently improve visual function. Furthermore, chemotherapy is associated with altered white matter microstructure in individuals with NF1-OPG, suggesting a detrimental effect on oligodendroglia. We analyzed the tumor-independent effects of carboplatin on oligodendrocytes in Nf1-mutant mice and evaluated pharmacological strategies for reducing this chemotherapy-associated toxicity. Methods: Carboplatin- or vehicle-treated Nf1+/− mice or Nf1-mutant optic glioma cells were employed to assess the effects of restorative interventions on optic nerve oligodendrocytes in vivo and tumor cell growth in vitro, respectively. Results: Clinically relevant carboplatin dosing induced oligodendrocyte loss and impaired myelin sheath structure in the optic nerves of Nf1+/− mice, an effect not observed following vinca alkaloids or MEK inhibitor (selumetinib) treatment. Carboplatin downregulates genes essential for cholesterol biosynthesis and decreases cholesterol levels in Nf1+/− optic nerves, such that dietary cholesterol supplementation after carboplatin exposure restored oligodendrocyte numbers. Carboplatin also increases the density of monocytes (microglia/macrophages) in the Nf1+/− optic nerves. Using PLX5622 (a CSF1R inhibitor) to reduce monocyte numbers or using clemastine to promote the generation and survival of oligodendrocytes, alleviated the oligodendrocyte loss caused by carboplatin treatment. Notably, PLX5622 and clemastine reduced the viability of Nf1-mutant optic glioma tumor cells. Conclusions: Our findings demonstrate that carboplatin induces oligodendroglial toxicity in Nf1-mutant optic nerves, which can be mitigated by clemastine, PLX5622, or dietary cholesterol following carboplatin exposure.
- 1 July 2020
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (13_Supplem) , A78
Abstract A78: Pre-existing, poly-resistant cancer stem cells in high-grade serous ovarian cancer
High-grade serous ovarian carcinoma (HGSOC) is the most common and lethal form of epithelial ovarian cancer. While HGSOCs respond well to platinum and taxane chemotherapy, the majority of patients eventually relapse with treatment-resistant tumors. This new and ominous resistance property of recurrent tumors is generally thought to be acquired in a process aided by the mutagenic activities of the chemotherapy itself. However, using advanced and robust technology that enables the direct cloning of cancer stem cells (CSCs) from HGSOCs, our study challenges the notion that chemotherapy resistance is acquired. In particular, patient-specific “libraries” of CSCs generated from therapy-naive tumors show that, while the majority of the CSCs are rapidly killed by platinum-taxane treatment, a discrete subset is highly resistant to these drugs to which they had no prior exposure. More telling is that these pre-existing, platinum-taxane resistant CSCs also display a profound “polyresistance” to a wide range of unrelated chemotherapeutic drugs. Importantly, gene expression profiles of polyresistant CSCs are highly uniform within a particular patient and clearly distinct from those of sensitive clones. This finding suggests that resistant clones within a patient carry the same gene signature, suggesting that resistance is a singular and knowable event in each patient. Comparing the resistance gene expression signatures across patients is revealing a very limited set of common pathways involving nuclear receptors that likely hold the key to the polyresistance phenomena. Taken together, our study supports the concept that these poly-resistant variants exist and can be cloned from most if not all HGOC patients. Further, the cloning of these polyresistant cells sets in motion the possibility that such variants can be exploited to identify both key pathways of polyresistance and drugs that specifically and pre-emptively eliminate these clones to prevent onset of recurrent disease. Citation Format: Jingzhong Xie, Yusuke Yamamoto, Audrey-Ann Liew, Bailiang Wang, Rajasekaran Mahalingam, Marcin Duleba, Wei Rao, Suchan Niroula, Kristina Goller, Yanting Zhang, Shan Wang, Amir Jazaeri, Peter Davies, Suzy Torti, Giulio Draetta, Matthew Anderson, Molly Brewer, Christopher Crum, Frank McKeon, Wa Xian. Pre-existing, poly-resistant cancer stem cells in high-grade serous ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr A78.
- 1 July 2020
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (13_Supplem) , A78
Abstract A78: Pre-existing, poly-resistant cancer stem cells in high-grade serous ovarian cancer
High-grade serous ovarian carcinoma (HGSOC) is the most common and lethal form of epithelial ovarian cancer. While HGSOCs respond well to platinum and taxane chemotherapy, the majority of patients eventually relapse with treatment-resistant tumors. This new and ominous resistance property of recurrent tumors is generally thought to be acquired in a process aided by the mutagenic activities of the chemotherapy itself. However, using advanced and robust technology that enables the direct cloning of cancer stem cells (CSCs) from HGSOCs, our study challenges the notion that chemotherapy resistance is acquired. In particular, patient-specific “libraries” of CSCs generated from therapy-naive tumors show that, while the majority of the CSCs are rapidly killed by platinum-taxane treatment, a discrete subset is highly resistant to these drugs to which they had no prior exposure. More telling is that these pre-existing, platinum-taxane resistant CSCs also display a profound “polyresistance” to a wide range of unrelated chemotherapeutic drugs. Importantly, gene expression profiles of polyresistant CSCs are highly uniform within a particular patient and clearly distinct from those of sensitive clones. This finding suggests that resistant clones within a patient carry the same gene signature, suggesting that resistance is a singular and knowable event in each patient. Comparing the resistance gene expression signatures across patients is revealing a very limited set of common pathways involving nuclear receptors that likely hold the key to the polyresistance phenomena. Taken together, our study supports the concept that these poly-resistant variants exist and can be cloned from most if not all HGOC patients. Further, the cloning of these polyresistant cells sets in motion the possibility that such variants can be exploited to identify both key pathways of polyresistance and drugs that specifically and pre-emptively eliminate these clones to prevent onset of recurrent disease. Citation Format: Jingzhong Xie, Yusuke Yamamoto, Audrey-Ann Liew, Bailiang Wang, Rajasekaran Mahalingam, Marcin Duleba, Wei Rao, Suchan Niroula, Kristina Goller, Yanting Zhang, Shan Wang, Amir Jazaeri, Peter Davies, Suzy Torti, Giulio Draetta, Matthew Anderson, Molly Brewer, Christopher Crum, Frank McKeon, Wa Xian. Pre-existing, poly-resistant cancer stem cells in high-grade serous ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr A78.
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
234 - Epigenetic Patterning of the Human Gastrointestinal Tract Parallels Fly Development
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
234 - Epigenetic Patterning of the Human Gastrointestinal Tract Parallels Fly Development
- Open Access
- 18 January 2018
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 24 (suppl_1) , S28
P078 MUCOSAL STEM CELL HETEROGENEITY IN PEDIATRIC CROHN’S DISEASE
Crohn’s is an aggressive inflammatory bowel disease driven by interactions of unknown relative significance between the immune system, the microbiome, and the intervening intestinal epithelial barrier. Histopathology analyses and genome-wide association studies (GWAS) have provided renewed focus on the role of the mucosal barrier in this disease. We obtained endoscopic biopsies from 30 patients either newly diagnosed with Crohn’s, under treatment for Crohn’s, or functional controls. Using stem cell cloning technology that maintains cells in their most immature ground state with the potential for conditional differentiation to a mature epithelium1, we analyzed stem cells from each of these cases. We find that pediatric patients with Crohn’s harbor two populations of mucosal stem cells including one that is similar to children without Crohn’s and a second distinguished by three epigenetically maintained traits that are potentially pathogenic. These traits include a robust inflammatory gene signature including many implicated by GWAS in the risk for Crohn’s, defective secretory cell differentiation impacting barrier function, and a profound homeotic transformation of terminal ileum to proximal gastrointestinal tract. Our epistasis analyses indicate that the homeotic transformation dictates both the inflammatory and barrier defects and underlies the absolute concurrence of these traits across cases. Our analysis of barrier function of epithelia formed from these aberrant stem cells shows their enhanced sensitivity to bacterial components, and the pattern of chemokines and cytokines produced by these cells promotes leukocyte extravasation. These findings link an epigenetically distinct subpopulation of intestinal stem cells and the defective epithelial they beget to the pathophysiology of Crohn’s and may reframe therapeutic strategies in this disease.
- 18 January 2018
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 24 (suppl_1) , S28
Open AccessP078 MUCOSAL STEM CELL HETEROGENEITY IN PEDIATRIC CROHN’S DISEASE
Crohn’s is an aggressive inflammatory bowel disease driven by interactions of unknown relative significance between the immune system, the microbiome, and the intervening intestinal epithelial barrier. Histopathology analyses and genome-wide association studies (GWAS) have provided renewed focus on the role of the mucosal barrier in this disease. We obtained endoscopic biopsies from 30 patients either newly diagnosed with Crohn’s, under treatment for Crohn’s, or functional controls. Using stem cell cloning technology that maintains cells in their most immature ground state with the potential for conditional differentiation to a mature epithelium1, we analyzed stem cells from each of these cases. We find that pediatric patients with Crohn’s harbor two populations of mucosal stem cells including one that is similar to children without Crohn’s and a second distinguished by three epigenetically maintained traits that are potentially pathogenic. These traits include a robust inflammatory gene signature including many implicated by GWAS in the risk for Crohn’s, defective secretory cell differentiation impacting barrier function, and a profound homeotic transformation of terminal ileum to proximal gastrointestinal tract. Our epistasis analyses indicate that the homeotic transformation dictates both the inflammatory and barrier defects and underlies the absolute concurrence of these traits across cases. Our analysis of barrier function of epithelia formed from these aberrant stem cells shows their enhanced sensitivity to bacterial components, and the pattern of chemokines and cytokines produced by these cells promotes leukocyte extravasation. These findings link an epigenetically distinct subpopulation of intestinal stem cells and the defective epithelial they beget to the pathophysiology of Crohn’s and may reframe therapeutic strategies in this disease.
- 1 January 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (1) , S40
P078 MUCOSAL STEM CELL HETEROGENEITY IN PEDIATRIC CROHN’S DISEASE
- 1 January 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (1) , S40
P078 MUCOSAL STEM CELL HETEROGENEITY IN PEDIATRIC CROHN’S DISEASE